Carmustine is a chemotherapy drug used primarily to treat brain tumors, certain blood cancers, and lymphomas. Also known by its chemical abbreviation BCNU, it belongs to a class of drugs called nitrosoureas, which work by damaging the DNA inside cancer cells to stop them from dividing. What makes carmustine unusual among chemotherapy agents is its ability to cross from the bloodstream into the brain, a barrier most drugs cannot penetrate.
How Carmustine Works
Carmustine kills cancer cells by creating abnormal links between the two strands of DNA inside a cell. These cross-links prevent the cell from copying its DNA, which it must do before it can divide. The drug also disrupts RNA, blocking the cell’s ability to produce proteins it needs to survive.
Beyond its direct attack on genetic material, carmustine interferes with a protective enzyme that cells use to neutralize toxic molecules. By disabling this defense system, the drug makes cancer cells more vulnerable to damage they would otherwise repair. This dual mechanism, targeting both DNA and cellular repair pathways, is part of why carmustine remains effective even in cancers that have developed resistance to other chemotherapy drugs in the same broad category.
What Carmustine Treats
Carmustine’s ability to reach the brain makes it especially valuable for central nervous system cancers. Its FDA-approved uses include:
- Brain tumors: glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and cancers that have spread to the brain from other parts of the body
- Multiple myeloma: a blood cancer, treated in combination with other medications
- Hodgkin’s lymphoma: when the disease has returned or stopped responding to earlier treatment
- Non-Hodgkin’s lymphoma: also for relapsed or treatment-resistant cases
In lymphoma treatment, carmustine plays a key role in a well-known combination regimen called BEAM, which is used to prepare patients for stem cell transplants. In this protocol, carmustine is given as a single intravenous dose six days before the transplant, alongside three other chemotherapy drugs given on a staggered schedule over the following days. The goal is to destroy remaining cancer cells and suppress the immune system enough to accept the transplanted stem cells.
Two Ways It’s Given
Carmustine is delivered in two very different forms depending on the situation. The traditional route is intravenous infusion, where the drug is dissolved and dripped into a vein over a period of hours. The standard dose for patients who haven’t received prior treatment ranges from 150 to 200 mg per square meter of body surface area, given once every six weeks. Some treatment plans split this into two smaller doses on consecutive days.
The six-week gap between cycles isn’t arbitrary. Carmustine’s effects on blood cell counts are delayed, with the lowest point often not arriving until weeks after the infusion. Doctors monitor blood counts weekly to confirm that white blood cells and platelets have recovered to safe levels before the next round.
Carmustine Wafers for Brain Tumors
For brain tumors, carmustine can also be delivered directly into the brain through small biodegradable wafers known by the brand name Gliadel. During surgery to remove a brain tumor, a surgeon lines the cavity left behind with these thin, disc-shaped implants. Each wafer is saturated with carmustine and slowly dissolves over time, releasing the drug right where residual cancer cells are most likely to be lurking at the edges of the surgical site.
This approach was designed as a therapeutic bridge, delivering continuous treatment during the weeks between surgery and the start of standard radiation and chemotherapy. A large phase 3 trial across 14 countries found that newly diagnosed patients with malignant glioma who received these wafers survived a median of 13.9 months, compared to 11.6 months for those who received placebo wafers. That translates to a 29% reduction in the risk of death. For patients with recurrent brain tumors, the benefit was similar: median survival of 31 weeks with carmustine wafers versus 23 weeks without.
The wafers aren’t appropriate for every patient. When surgery requires opening the brain’s ventricular system (the fluid-filled chambers deep inside the brain), wafers can migrate into those spaces and cause dangerous complications, including a buildup of fluid pressure called hydrocephalus.
Side Effects and Risks
Like most chemotherapy drugs, carmustine suppresses the bone marrow’s ability to produce blood cells. This is its most common serious side effect and the reason treatment cycles are spaced six weeks apart. Drops in white blood cells increase infection risk, while low platelet counts raise the chance of bleeding. Because this effect is cumulative, meaning it can worsen with each treatment cycle, blood counts are tracked closely throughout the course of therapy.
The side effect that distinguishes carmustine from many other chemotherapy drugs is lung toxicity. Carmustine can cause inflammation and scarring (fibrosis) in the lungs, and this risk climbs significantly once the total lifetime dose exceeds 1,400 mg per square meter of body surface area. Cases of pulmonary fibrosis have been reported at lower cumulative doses as well, so lung function is typically monitored throughout treatment. Symptoms can include shortness of breath, a persistent dry cough, and reduced exercise tolerance.
Other common side effects include nausea and vomiting during or shortly after infusion, pain or irritation at the injection site, and temporary flushing of the skin. Some patients experience liver enzyme elevations, which usually resolve but require monitoring.
Why It Crosses Into the Brain
The brain is protected by a tightly sealed network of blood vessels called the blood-brain barrier, which blocks most large or water-soluble molecules from entering brain tissue. Carmustine is a small, fat-soluble molecule, which allows it to slip through this barrier where many other chemotherapy agents cannot. This property is the primary reason carmustine has remained a cornerstone of brain tumor treatment for decades, despite newer drugs entering the oncology landscape. The wafer form bypasses the barrier entirely, delivering drug directly to brain tissue at concentrations far higher than intravenous infusion can achieve.